CareDx (CDNA) Q2 2026 earnings review
Massive One-Time Gains Mask Strong Core Expansion
CareDx delivered a complex but highly favorable Q2, heavily influenced by portfolio restructuring and historical cash collections. Top-line revenue surged 52% YoY to $132 million, but $16 million of this came from out-of-period cash collections. Bottom-line GAAP Net Income hit a staggering $111 million, driven entirely by a $113 million gain from divesting the Lab Products segment. Beyond the noise, the core business remains robust: testing volumes grew 17% YoY, Adjusted EBITDA expanded to $25 million (19% margin), and management confidently raised full-year guidance across the board.
🐂 Bull Case
Adjusted EBITDA margin has expanded from 6% a year ago to 19% today. The company successfully executed its strategy to exit lower-margin business (Lab Products) to focus strictly on high-margin testing services.
The operational turnaround in RCM continues to pay massive dividends. The ability to collect on previously denied or delayed claims is structurally boosting cash flow and average selling prices (ASP).
🐻 Bear Case
The reported 61% YoY growth in Testing Services revenue is heavily skewed by $16M in prior period collections. The underlying testing revenue growth is a more grounded 28%.
The finalization of the MolDX LCD for solid organ transplant testing remains a critical macro uncertainty. While deferred, any adverse limitations on surveillance testing frequency could alter the long-term volume trajectory.
⚖️ Verdict: 🟢
Bullish. While the headline numbers are inflated by one-time items (divestiture gains and out-of-period collections), the underlying 28% core testing growth and expanding EBITDA margins show a highly disciplined, rapidly scaling business.
Key Themes
Strategic Portfolio Transformation Complete
Management executed a flawless portfolio pivot this quarter. By closing the sale of the Lab Products business to Eurobio Scientific, CareDx netted a $113M gain and shed a lower-margin, slower-growing segment (8% YoY growth). Simultaneously, the integration of Naveris provides a focused entry into specialty oncology. This leaves a cleaner, higher-margin operating model purely focused on precision diagnostics.
Digital Solutions Driving Pull-Through
Patient and Digital Solutions revenue accelerated dramatically, growing 50% YoY to $19 million. This validates management's 'solution selling' thesis: by embedding digital workflow tools (like Epic Aura integrations and MedActionPlan) directly into transplant center operations, CareDx is successfully driving loyalty and securing higher Testing Services volume.
Testing Volume Resilience
Underlying test volume grew 17% YoY to approximately 58,000 tests. This stable, sequential volume expansion proves that the adoption of molecular surveillance protocols remains deeply entrenched in clinical standard-of-care, insulating the company against broader macro procedure volatility.
Reliance on Out-of-Period Collections
A key contradiction to the positive revenue narrative: Testing Services revenue officially grew an explosive 61% YoY. However, this includes a massive $16 million in cash collected from prior periods (up from $14M in Q1 and $5M in Q4). Management acknowledges that excluding these delayed claims, the underlying testing revenue grew 28%. As these historical claims are flushed out, CareDx faces very difficult revenue comps in late 2026 and 2027.
MolDX LCD Macro Overhang
The CMS Medicare coverage policy for molecular testing in transplant care (MolDX LCD) remains an unresolved macro-level risk. While the company stated that CMS recently finalized a policy supporting continued access to AlloSure and AlloMap, the precise limits on long-term testing frequency remain a lingering threat to the terminal value of the surveillance model.
Innovation and Evidence Generation Advancing
CareDx continues to fortify its moat through aggressive clinical evidence generation. The quarter featured published data for HistoMap Kidney in 'Transplantation', expanding molecular assessment into tissue biopsies. Furthermore, the company submitted a clinical validation manuscript for AlloHeme, signaling CLIA readiness for its imminent push into cell therapy monitoring.
Naveris Integration Risk
With the Naveris acquisition closed, CareDx must now execute outside of its traditional solid organ transplant comfort zone. NavDx (for HPV-driven cancers) requires CareDx to leverage its specialty oncology channels effectively. Any friction in scaling this new commercial team could threaten the 30-40% growth trajectory previously projected for this asset.
Other KPIs
A massive reversal from a $9 million loss a year ago. However, investors must back out the $113 million gain on the sale of the Lab Products business to understand operational profitability. Non-GAAP Net Income of $20 million is the cleaner metric for analyzing core operations.
Accelerating significantly from previous quarters (was ~$1,400-1,460 range). This spike is heavily distorted by the $16 million in out-of-period cash collections divided over the 58,000 tests. The structural, go-forward ASP is lower, though structurally improving due to RCM efficiencies.
Explosive growth from $65.4 million at year-end 2025. This fortress balance sheet was achieved via $31 million in Q2 operational cash flow combined with the upfront cash proceeds from the Lab Products divestiture, providing ample runway for the $100M share buyback and Naveris integration.
Guidance
Accelerating. Raised considerably from the prior range of $447M - $465M. This is particularly impressive because the second half of the year will no longer include revenue from the divested Lab Products segment (which historically generated ~$12-13M per quarter). The raise implies intense confidence in core testing and digital solutions.
Accelerating. Raised significantly from the prior $43M - $57M range. The shedding of the lower-margin Lab Products division, combined with exceptional RCM cash collections, provides a clear tailwind to operating leverage heading into the back half of the year.
Key Questions
Depletion of Out-of-Period Claims
You recorded $16M in prior period revenue this quarter, up from $14M in Q1. How much of this historical backlog is left to process, and how should we model the sequential step-down in Average Revenue Per Test as this tailwind fades in Q3 and Q4?
Naveris Contribution to Guidance
Does the raised FY26 revenue guidance of $490M-$500M include expected contributions from the newly acquired Naveris business, or is it strictly reflecting the organic CareDx testing and digital solutions portfolio?
Lab Products Transition Agreement
With the sale of Lab Products to Eurobio Scientific complete, what are the exact economics and duration of the transition services agreement, and how will it impact OPEX in the second half of the year?
MolDX Final LCD Impact
You previously baked a $7.5M negative impact into H2 2026 guidance regarding the MolDX LCD. Now that CMS has finalized the Medicare coverage policy, has that expected financial headwind changed, and did it factor into the guidance raise?